Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research.

conditioned pain modulation descending control of nociception descending pain control diffuse noxious inhibitory controls endogenous pain modulation monoamines

Journal

Journal of pain research
ISSN: 1178-7090
Titre abrégé: J Pain Res
Pays: New Zealand
ID NLM: 101540514

Informations de publication

Date de publication:
2021
Historique:
received: 12 02 2021
accepted: 06 04 2021
entrez: 28 4 2021
pubmed: 29 4 2021
medline: 29 4 2021
Statut: epublish

Résumé

Bulbospinal pathways regulate nociceptive processing, and inhibitory modulation of nociception can be achieved via the activity of diffuse noxious inhibitory controls (DNIC), a unique descending pathway activated upon application of a conditioning stimulus (CS). Numerous studies have investigated the effects of varied pharmacological systems on the expression status of a) DNIC (as measured in anaesthetised animals) and b) the descending control of nociception (DCN), a surrogate measure of DNIC-like effects in conscious animals. However, the complexity of the underlying circuitry that governs initiation of a top-down inhibitory response in reaction to a CS, coupled with the methodological limitations associated with using pharmacological tools for its study, has often obscured the exact role(s) of a given drug. In this literature review, we discuss the pharmacological manipulation interrogation strategies that have hitherto been used to examine the functionality of DNIC and DCN. Discreet administration of a substance in the spinal cord or brain is considered in the context of action on one of four hypothetical systems that underlie the functionality of DNIC/DCN, where interpreting the outcome is often complicated by overlapping qualities. Systemic pharmacological modulation of DNIC/DCN is also discussed despite the fact that the precise location of drug action(s) cannot be pinpointed. Chiefly, modulation of the noradrenergic, serotonergic and opioidergic transmission systems impacts DNIC/DCN in a manner that relates to drug class, route of administration and health/disease state implicated. The advent of increasingly sophisticated interrogation tools will expedite our full understanding of the circuitries that modulate naturally occurring pain-inhibiting pathways.

Identifiants

pubmed: 33907456
doi: 10.2147/JPR.S258602
pii: 258602
pmc: PMC8068490
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1083-1095

Subventions

Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/T002115/1
Pays : United Kingdom

Informations de copyright

© 2021 Kucharczyk et al.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Références

J Biomed Sci. 2010 Mar 19;17(1):19
pubmed: 20302612
Brain Res. 1998 Aug 24;803(1-2):208-11
pubmed: 9729390
J Pain. 2011 Jun;12(6):687-97
pubmed: 21330219
Neuroscience. 1990;37(3):809-18
pubmed: 2247225
J Neurophysiol. 1986 Oct;56(4):1185-95
pubmed: 3783235
Pain. 2018 May;159(5):919-928
pubmed: 29369967
J Neurophysiol. 1994 Sep;72(3):1152-60
pubmed: 7807200
Pain. 2011 Aug;152(8):1821-1831
pubmed: 21514054
Brain Res. 1982 Mar 25;236(2):329-37
pubmed: 6978166
Brain Res. 1981 Jul 20;216(2):313-21
pubmed: 6454457
Pain. 2009 Apr;142(3):245-254
pubmed: 19231081
J Neurophysiol. 2019 Jan 1;121(1):96-104
pubmed: 30461363
Brain Res. 1981 Jan 12;204(2):387-402
pubmed: 6257327
J Pharmacol Exp Ther. 1988 Oct;247(1):332-42
pubmed: 3171978
Nat Neurosci. 2018 Jun;21(6):869-880
pubmed: 29686262
Exp Neurol. 2020 Nov;333:113428
pubmed: 32745472
J Neurosci. 2002 May 15;22(10):4103-13
pubmed: 12019329
Cephalalgia. 2019 Apr;39(5):617-625
pubmed: 30286616
Exp Physiol. 2002 Mar;87(2):245-9
pubmed: 11856970
Eur J Neurosci. 2020 Feb;51(4):952-962
pubmed: 31518451
Eur J Pain. 2019 Jul;23(6):1185-1195
pubmed: 30821870
Brain Res. 1983 Sep 19;275(1):1-11
pubmed: 6626970
Brain Res. 1996 Nov 18;740(1-2):201-7
pubmed: 8973815
Eur J Pharmacol. 1992 Jun 5;216(2):149-56
pubmed: 1397003
Pain. 2010 Jun;149(3):483-494
pubmed: 20399562
Eur J Pharmacol. 2016 Aug 5;784:61-8
pubmed: 27178898
Behav Brain Res. 1990 Jul 9;39(2):97-111
pubmed: 2390201
Pain. 2019 Jul;160(7):1614-1621
pubmed: 30870321
Pain. 2021 Jan 15;:
pubmed: 33470750
Eur J Pharmacol. 1988 Mar 29;148(2):273-7
pubmed: 3378576
Neuron. 2017 Feb 22;93(4):822-839.e6
pubmed: 28162807
Pain. 2020 Mar;161(3):609-618
pubmed: 31725062
Neuroscience. 1995 Dec;69(3):931-8
pubmed: 8596660
Headache. 2012 Feb;52(2):262-73
pubmed: 21929659
J Neurosci. 2013 Jul 10;33(28):11703-14
pubmed: 23843537
Life Sci. 1983;33 Suppl 1:549-52
pubmed: 6664236
Brain Res. 1981 Feb 16;206(2):495-9
pubmed: 6260285
Brain Res. 1982 Jan 14;231(2):461-5
pubmed: 6976820
Eur J Pain. 2017 Apr;21(4):750-760
pubmed: 27891703
Pain. 2015 Sep;156(9):1803-1811
pubmed: 26010460
J Med Dent Sci. 2009 Mar;56(1):17-24
pubmed: 19697515
Brain Res. 1981 Jun 29;215(1-2):257-74
pubmed: 7260590
Neurosci Lett. 2020 Jun 11;729:134990
pubmed: 32315711
J Neurosci. 2009 Dec 16;29(50):15828-35
pubmed: 20016098

Auteurs

Mateusz Wojciech Kucharczyk (MW)

Central Modulation of Pain Group, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE1 1UL., UK.

Diego Valiente (D)

Central Modulation of Pain Group, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE1 1UL., UK.

Kirsty Bannister (K)

Central Modulation of Pain Group, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE1 1UL., UK.

Classifications MeSH